First-in-Human Trials: Strategy That Puts Patients First

A well-executed strategy is critical to the success of your first-in-human (FIH) oncology program. Are you prepared?

First-in-human (FIH) oncology trials demand more than operational excellence — they require a strong strategic foundation built on experience, foresight, and regulatory insight.

To help clinical teams navigate these high-stakes trials with greater confidence, we’ve developed a guide that outlines key strategies for de-risking early oncology programs, accelerating timelines, and enhancing patient outcomes.

In this strategic guide, you’ll learn:

What matters most when designing and planning FIH oncology studies
Common pitfalls — and how to avoid them
Regulatory considerations that shape trial success
Leveraging expert consulting to mitigate risk

Download the guide today and move forward with confidence.

Access the Guide Now

Download Case Studies

Real-World Application

Whether you're preparing your first IND or managing post-market obligations, Ergomed Consulting provides expert regulatory guidance and a trusted partnership for a success in rare disease and oncology development.

Partner with Experts Who Have Done It Before

Speak with one of our experts today to explore how Ergomed Clinical Research can support your next study.